RxDoctor Payments Data

Colleen Jennings

Nurse Practitioner · Philadelphia, PANPI 1942771001

Payments from drug & device makers

$1,605in general payments, 2019–2025

Across 46 payments — averaging $34.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$254
  • Sanofi-aventis U.S. LLC$215
  • AstraZeneca$200
  • Astellas Pharma US Inc$159
  • Amgen$151
  • Medtronic$115
  • plus $510 from 11 others

What the payments were for

  • Consulting fees$17511%
  • Travel & lodging$25416%
  • Food & beverage$1,09068%
  • Education$865%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,605 in reported general payments places this provider in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$47,818
Medicare patients
64
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide139$2,403,916
PomalystPomalidomide47$1,064,014
RezurockBelumosudil Mesylate25$443,814
Lenalidomide30$372,846
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5050$196,540
OctagamImmun Globg(Igg)/Malt/Iga Ov5023$145,035
EliquisApixaban49$31,951
Acyclovir155$2,360
Fluconazole28$1,260
Ondansetron Hcl30$971
Gabapentin25$616
Oxycodone Hcl26$559
Potassium Chloride28$524
Montelukast Sodium31$518
Pantoprazole Sodium51$507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCRezurock$215$443,81425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →